Status:

TERMINATED

LoBAG30 Diet in Patients on Metformin

Lead Sponsor:

US Department of Veterans Affairs

Conditions:

Diabetes Mellitus

Diet

Eligibility:

All Genders

50-70 years

Phase:

NA

Brief Summary

We will determine the metabolic response to a Low Biologically Available Glucose Diet (LoBAG30) in subjects currently receiving the maximum dose of metformin as monotherapy in whom the glycohemoglobin...

Detailed Description

Subjects will ingest a control diet (55% carbohydrate (CHO), 15% protein, 30% fat) or a LoBAG30 diet (30% CHO, 30% protein, 40% fat) in a parallel design with block randomization in pairs of two. Subj...

Eligibility Criteria

Inclusion

  • People with type 2 diabetes mellitus who currently are receiving the maximal dose of metformin monotherapy (2500 mg/day).
  • These subjects will have had a stable glycohemoglobin (tGHb) in an unacceptably high range (8-11%) for at least 4 months prior to beginning the study.
  • Subjects with tGHB \> 11% (HbA1c \> 10%) will not be recruited into the study.

Exclusion

  • Hematological abnormalities
  • liver disease
  • kidney disease
  • macroalbuminuria (\>300 mg albumin/24 hours)
  • untreated thyroid disease
  • congestive heart failure
  • angina
  • life-threatening malignancies
  • proliferative retinopathy
  • severe diabetic neuropathy
  • peripheral vascular disease
  • serious psychological disorders
  • a body mass index \> 35
  • and a fasting triglyceride of \>400 mg/dl.
  • Subjects taking slow-release metformin will not be studied.
  • Subjects taking medications other than metformin, known to affect fuel metabolism such as:
  • insulin
  • the sulfonylureas
  • glucagon-like peptide 1 (GLP-1) analogs and metabolic inhibitors
  • pramlintide
  • prednisone and similar steroids
  • thyroid hormone
  • antipsychotic medications
  • thiazide diuretics
  • medroxyprogesterone
  • high dose aspirin, also will be excluded.
  • If concentrations of serum folate, B12 or iron are low, the subject will be excluded from the study until corrected, i.e. until normal concentrations are recorded.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2011

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00607867

Start Date

April 1 2008

End Date

March 1 2011

Last Update

December 12 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

VA Medical Center, Minneapolis

Minneapolis, Minnesota, United States, 55417